BRIEF—Pfizer buys rights to type 1 diabetes candidate

Pfizer has exercised an option on an immune tolerance therapy from privately-held immunotherapy specialist AnTolRx.

The firm bought the option on a therapy from AnTolRx's type 1 diabetes program in June 2016.

Pfizer gains exclusive rights to pursue development of the candidate and will be responsible for all further development and commercialization.

AnTolRx will receive an unspecified upfront payment plus potential milestone and royalty payments.